Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis Invests In Start-up Sideris

by Michael McCoy
October 28, 2013 | A version of this story appeared in Volume 91, Issue 43

Novartis has signed a pact giving it the exclusive right to acquire Sideris Pharmaceuticals, a University of Florida spin-off, for up to $300 million. The deal is a companion to a $32 million fund-raising round for the biotech firm that was led by the venture capital company MPM Capital. Based in Boston and Gainesville, Fla., Sideris has developed SP-420, a small molecule that selectively binds iron and removes it from the body. It is intended to treat iron overload caused by multiple transfusions.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.